VFA
ADPT icon

Valeo Financial Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Valeo Financial Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-212
Closed -$9K – 537
2021
Q1 		$9K Sell
212
-9
-4% -$487 ﹤0.01% 1377
2020
Q4 		$13K Hold
221
– – ﹤0.01% 1122
2020
Q3 		$11K Hold
221
– – ﹤0.01% 1053
2020
Q2 		$11K Hold
221
– – ﹤0.01% 1244
2020
Q1 		$6K Buy
221
+163
+281% +$4.55K ﹤0.01% 1235
2019
Q4 		$2K Hold
58
– – ﹤0.01% 1434
2019
Q3 		$2K Buy
+58
New +$2.37K ﹤0.01% 1358

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Valeo Financial Advisors's ADPT Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 212 shares — an estimated $9K sold.

Valeo Financial Advisors first reported a position in ADPT in Q3 2019 and held it in 7 quarters. The position peaked at $13K in Q4 2020. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 212 Adaptive Biotechnologies shares in Q2 2021, an estimated $9K.
  • Valeo Financial Advisors first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 7 quarters.
  • Valeo Financial Advisors's Adaptive Biotechnologies position peaked at $13K in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.